Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

Publish Date : 28-Mar-2016

The world's leading provider of proton therapy solutions for the treatment of cancer, IBA (Ion Beam Applications SA), has announced signing of a contract with the University Hospitals Leuven (UZ Leuven) and Katholieke Universiteit Leuven (KU Leuven) for installation of Belgium's first proton therapy center in a project with Universite Catholique de Louvain (UCL), Cliniques universitaires Saint-Luc and other Belgian universities. The contract was awarded to IBA following a comprehensive European public tender conducted by UZ Leuven.

The new center will be equipped by IBA with its Proteus ONE* system. Additionally, the contract covers a long-term maintenance agreement. The expected end-user price for a Proteus ONE system with such a maintenance contract is between EUR 35 and 40 million. Opening of this new center is scheduled for 2018.

Olivier Legrain, Chief Executive Officer of IBA said, We are excited to have been selected to install Belgium's first proton therapy center, bringing access to the most advanced radiation therapy technology to Belgian cancer patients. We are proud to install our cutting edge Proteus ONE system so close to our headquarters and we look forward to collaborating with leading institutions like UZ Leuven, KU Leuven, UCL, Saint-Luc, and the other Belgian universities involved in the project."

Marc Decramer, Chief Executive Officer of UZ Leuven said, We are very pleased to announce that we will be working with IBA. The UZ Leuven mission is to deliver the highest quality and most innovative patient care with unrelenting attention to clinical excellence, patient care and patient safety. It was therefore a natural decision for us to equip our hospital with a proton therapy solution as it is the most targeted treatment in the fight against cancer. Following a comprehensive public tender, we have chosen IBA because it provided the proton therapy solution that best fitted our needs."

Go to previous page